A bit more info from the Biota press release in relation to the purchase of Prolysis:
Prolysis has two primary projects focussed on new antibiotics for multiple drug resistant infections. If successfully developed, they have the potential to manage the current wave of hospital superbugs that are prevalent in modern society. The two key programs acquired are: ? A Gyrase program targeting DNA supercoiling in gram positive bacteria; and ? A Cell Division Inhibitor (CDI) program targeting staphylococci, blocking assembly of the septum cell wall components prior to cell division. This program has received significant Wellcome Trust funding over recent years.
